ASCO 2015 | Neoadjuvant abiraterone acetate plus leuprolide acetate in localised high-risk prostate cancer
Eleni Efstathiou
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Eleni Efstathiou, MD, PhD, from The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of a study that evaluated the clinical and biological heterogeneity of response and resistance to neoadjuvant abiraterone acetate, a prodrug of abiraterone, a CYP17 inhibitor that lowers serum testosterone, plus leuprolide acetate, a luteinizing hormone-releasing hormone agonist (LHRHa), versus LHRHa in patients with localised high-risk prostate cancer.
Related videos

Targeted screening and risk stratification of prostate cancer - updates from the IMPACT study
Rosalind Eeles

Erdafitinib and hyperphosphatemia in advanced UrC
Scott Tagawa

Kidney cancer: minimizing toxicities and hassle in adjuvant therapy
Tim Eisen

TROPHY-U-01: Initial findings
Scott Tagawa

Updates on JAVELIN renal 101: primary treatment for patients
Laurence Albiges
More from Eleni Efstathiou